The 12 most recent market catalysts affecting $AGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40
Chardan Capital's initiation of coverage on Agenus with a 'Buy' rating and a $40 price target is a positive development for the company. Analyst coverage, especially with a favorab…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
Agenus Says Published Phase 1b Data Showed 21.2-Month Median Overall Survival, 33% Three-Year Overall Survival And 21% Objective Response Rate With Botensilimab Plus Balstilimab In 123 Pretreated MSS Colorectal Cancer Patients
The positive Phase 1b data for Agenus's botensilimab plus balstilimab in pretreated MSS colorectal cancer patients is a significant corporate catalyst. The reported 21.2-month medi…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 65
Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
Agenus has filed an 8-K indicating that selling securityholders are offering a substantial number of common shares, up to 77,976,718. This is a secondary offering, which means the …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Agenus announced its Q2 sales, which came in at $34.5 million, surpassing the consensus estimate of $34.0 million. More significantly, this represents a 34.24% increase compared to…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Agenus shares are trading higher after B. Riley Securities raised its price target on the stock from $8 to $14.
The substantial increase in Agenus's price target from $8 to $14 by B. Riley Securities is a significant positive catalyst for the stock. This upgrade suggests that the analyst fir…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
B. Riley Securities analyst Mayank Mamtani has maintained a 'Buy' rating on Agenus and raised the price target from $8 to $14. This substantial increase in the price target, nearly…
Jul 13, 2026
Market Technicals
Bullish
Impact 60
12 Health Care Stocks Moving In Monday's Intraday Session
This filing, generated by an automated content engine, simply reports the intraday price movements of 12 healthcare stocks. It doesn't disclose any specific corporate catalysts, ne…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30
HC Wainwright & Co. analyst Emily Bodnar has maintained a 'Buy' rating on Agenus (AGEN) and raised the price target from $23 to $30. This upgrade signals increased confidence from …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 95
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
Agenus secured a substantial private placement of $85 million, with the potential for an additional $255 million through warrant exercises, extending its cash runway to 2031. Cruci…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Agenus shares are trading higher safter the company announced it will raise $85 million to fund its colon cancer drug trial.
This headline is a significant corporate catalyst for Agenus. The successful $85 million capital raise provides crucial funding for its colon cancer drug trial, alleviating immedia…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 85
Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised
Agenus Inc. has secured a significant financing package, starting with $85 million upfront and potentially reaching $340 million through warrant exercises. This capital infusion is…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.